Overview

Efficacy and Safety of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes

Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
This mechanistic study is designed to investigate the effect of vildagliptin on the sensitivity of the a-cell to glucose under hypoglycemic conditions in patients with type 2 diabetes (T2DM).
Phase:
Phase 3
Details
Lead Sponsor:
Novartis
Treatments:
Glucagon
Vildagliptin